|
Case Studies in Lymphoma Vol. 6, No. 2 Release date: May 5,
2008 Table of Contents
|
||||
| Instructions for Participation | ||||
|
||||
| Overview and Purpose | ||||
T-cell lymphomas (TCLs), which include cutaneous TCL and peripheral TCL (PTCL), account for 10% of all non-Hodgkin lymphomas and are challenging malignancies to treat due to disease heterogeneity, chemotherapy resistance, and lack of available targeted therapies. While standard first-line therapy for PTCL is similar to that used to treat B-cell lymphomas, no standard second-line therapy exists for PTCL. However, second-line therapeutic options have been developed and are under investigation in that disease, including anti-CD52 antibodies, proteasome inhibitors, chemotherapeutic agents, and immunotoxins. Histone deacetylase inhibitors (HDACIs) also represent a new class of agents that have demonstrated clinical efficacy and a manageable toxicity profile in patients with PTCL. The purpose of this activity is to update physicians on the use of HDACIs in the treatment of patients with PTCL. |
||||
| Target Audience | ||||
| This activity is intended for medical oncologists and hematologists involved in the care of patients with peripheral T-cell lymphoma. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity. | ||||
| Learning Objectives | ||||
| Upon completion of this educational activity, you should be able to: | ||||
|
||||
| Accreditation and Credit Designation | ||||
| Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
||||
| Illustration | ||||
Positron emission tomography scans of a patient with peripheral T-cell lymphoma revealing lymphadenopathy prior to romidepsin therapy (left panel) and reduction in lymphadenopathy after 8 months of romidepsin therapy (right panel) |
||||
| Disclosure Policy | ||||
It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity. Richard L. Piekarz, MD, PhD PER Editorial Staff This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the article page. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings. |
||||
| Commercial Support | ||||
An educational grant for this activity was provided by Gloucester Pharmaceuticals. |
||||
| Software Requirements | ||||
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser. If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About. PC Users If you need to upgrade your Web browser, follow one of the links listed below:
|
||||
| Disclaimer | ||||
| The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. Please consult full prescribing information for any drugs or procedures discussed within. |
||||
| Privacy Policy | ||||
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045. All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher. ©Copyright 2008 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher. All correspondence should be directed to: |
||||
|
|
||||
